Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent van der Noort

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|May 2, 2015
Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative GroupSharon D Stoker, Maarten A Wildeman, Zlata Novalic, et al.
Oncology|August 22, 2016
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate CancerSushil K Badrising, Vincent van der Noort, Paul Hamberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
International Journal of Cancer|October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocolIlse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinomaChristi M J Steendam, Robert Peric, Nico C van Walree, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trialCornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, et al.
JAMA Oncology|December 6, 2016
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical TrialGeert A Cirkel, Paul Hamberg, Stefan Sleijfer, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|May 2, 2015
Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative GroupSharon D Stoker, Maarten A Wildeman, Zlata Novalic, et al.
Oncology|August 22, 2016
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate CancerSushil K Badrising, Vincent van der Noort, Paul Hamberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
International Journal of Cancer|October 16, 2025
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocolIlse A C Spiekman, Niven Mehra, Laurien J Zeverijn, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinomaChristi M J Steendam, Robert Peric, Nico C van Walree, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trialCornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, et al.
JAMA Oncology|December 6, 2016
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical TrialGeert A Cirkel, Paul Hamberg, Stefan Sleijfer, et al.
Pageof 11